Call number: LD2668 .T4 1963 G77 / Master of Science

Submitted by Ana Maria Fiscina Sampaio (fiscina@bahia.fiocruz.br) on 2012-10-23T17:32:31Z No. of bitstreams: 1 Juliana Rebouças de Oliveira Etiologia da pneumonia adquirida....pdf: 2505145 bytes, checksum: d0d9c1cc48dc6e014855686844968a82 (MD5) / Made available in DSpace on 2012-10-23T17:32:31Z (GMT). No. of bitstreams: 1 Juliana Rebouças de Oliveira Etiologia da pneumonia adquirida....pdf: 2505145 bytes, checksum: d0d9c1cc48dc6e014855686844968a82 (MD5) Previous issue date: 2012 / Universidade Federal da Bahia. Centro de Pesquisas Gonçalo Moniz. Salvador, Bahia, Brasil / Pneumonia adquirida na comunidade (PAC) é uma das principais causas de hospitalização e óbito em crianças menores de cinco anos, na maioria dos países em desenvolvimento. O controle da PAC depende do entendimento adequado da importância dos agentes etiológicos, o quê tem sido dificultado pela ausência de métodos sensíveis, específicos e disponíveis, para estabelecer a etiologia dos casos. Derrame pleural (DP) é a complicação mais frequente da PAC. A atual compreensão é de que DP ocorre em infecções bacterianas piogênicas, informação essa decorrente do uso restrito de métodos tradicionais e pouco sensíveis que investigam apenas etiologia bacteriana em crianças com PAC e DP. Objetivo principal deste estudo foi determinar a etiologia da PAC em crianças hospitalizadas com DP utilizando métodos abrangentes para investigação etiológica. Desenho do estudo: realizado estudo observacional prospectivo do tipo corte transversal realizado em um hospital público, Centro Pediátrico Professor Hosannah de Oliveira (Salvador-Bahia). Material e métodos: a coleta de dados ocorreu entre setembro de 2003 a maio de 2005. Crianças previamente saudáveis com idade inferior a cinco anos, hospitalizadas com PAC, foram incluídas neste estudo. Resultados: das 277 crianças selecionadas, 206 (74%) tiveram o diagnóstico de pneumonia confirmado pela radiografia de tórax avaliada por um especialista em radiologia pediátrica. A etiologia foi estabelecida em 165 (80%) crianças; nas quais foram encontrados, infecção bacteriana em 20%, viral 48,5% e co-infecção vírus-bactéria em 31,5%. Derrame pleural (DP) foi descrito em 25 casos (12%). Entre as crianças com DP, a etiologia foi estabelecida em 18 casos (72%) sendo infecção bacteriana 28%, viral 50% e viral-bacteriana 22%. Entre todos os 25 casos com DP, a frequência por grupos etiológicos foram: bacteriana 20%, viral 36%, viral-bacteriana 16% e não identificado 28%. Conclusão: infecção exclusivamente viral foi identificada em um terço das crianças internadas com PAC e DP, portanto, quando se faz ampla investigação etiológica para vírus e bactérias, DP não está associado a apenas infecções bacterianas. Estes resultados levantam a necessidade de investigar a etiologia do DP de forma abrangente, procurando agentes virais e bactérianos, pelo uso de métodos moleculares / Community-acquired pneumonia (CAP) is a major cause of hospitalization and death among children under five years old in most developing countries. The control of CAP depends on the appropriate understanding of the matter of etiologic agents, what has been impaired by the lack of sensitive, specific and available diagnostic methods to establish the etiology. Pleural effusion (PE) is the most frequent complication of CAP. The current understanding is that SD occurs mainly in pyogenic bacterial infections. Such idea is probably due to limited use of diagnostic methods that are traditional and less sensitive, and merely investigate bacterial etiology in children with CAP and PE. The main objective of this study was to determine the etiology of CAP in hospitalized children with PE using comprehensive methods for investigating the etiology. We conducted a prospective cross-sectional observational study, performed at a public hospital, the Professor Hosannah de Oliveira Pediatric Center (Salvador-Bahia-Brazil). Data collection occurred between September 2003 and May 2005.Previously healthy children younger than five years, hospitalized with CAP were included in this study. Results: among 277 children selected, 206 (74%) had diagnosis of pneumonia confirmed by chest radiographs evaluated by a specialist in pediatric radiology. The etiology was confirmed in 80% children, in which we found: bacterial infection in 20%, viral infection in 48.5% and co-infection viral-bacterial in 31.5%. Pleural effusion (PE) was reported in 25 cases (12%). Among children with PE, the etiology was established in 18 cases (72%), being bacterial infection in 28%, viral infection in 50% and viral-bacterial infection in 22%. Among all 25 cases with PE, the frequencies by etiological groups were: 20% bacterial, 36% viral, 16% bacterial-viral and 28% unidentified. Conclusion: Viral infection was identified in only one third of children hospitalized with CAP and PE; so when extensive etiologic investigation for viruses and bacteria is performed, PE is not associated exclusively with bacterial infections. These results raise the need to investigate the etiology of PE in a comprehensive way, looking for viral and bacterial agents, including the use of molecular methods.

Chemoattractant agents play a crucial role in the initiation of immune responses, by regulating the traffic and function of leucocyte populations. Their receptors are therefore considered as potential targets for the development of new therapies in the fields of cancer and inflammatory diseases. ChemR23, a previously orphan receptor discovered in the laboratory, is structurally related to receptors for chemoattractant agents. It is expressed on immature myeloid and plasmacytoid dendritic cells (mDCs and pDCs respectively), as well as on adipocytes, macrophages, NK and endothelial cells. Chemerin, the endogenous ligand of ChemR23, is abundant in various human samples originating from inflammatory diseases, including pleural effusions. Chemerin is secreted as an inactive precursor, prochemerin, and is activated by the removal of six or seven amino-acids from its carboxy-terminus by serine proteases, such as as cathepsin G and elastase. Chemerin acts as a chemoattractant agent of low nanomolar potency for macrophages, immature mDCs and pDCs. It is however more active on pDCs, in line with the higher expression of ChemR23 on these cells. pDCs possess important immunoregulatory properties in lung diseases, and their ability to secrete large amounts of type I interferon (IFN) upon viral infection makes them crucial players in anti-viral immunity.<p>According to these elements, and to the role of neutrophils in the physiopathology of many inflammatory lung diseases and in the generation of active chemerin, we began in 2007 to study the role of chemerin and its receptor ChemR23 in inflammatory lung diseases. We first characterized the mouse chemerin/ChemR23 system, and described that this system was very similar to the human one, in terms of distribution, pharmacology and functional properties. We then used wild type mice (WT) and mice invalidated for the receptor (ChemR23-/-) in various models of inflammatory lung diseases, including asthma, lung fibrosis, viral pneumonia, and acute lung injury. <p>Whereas the asthma and lung fibrosis models did not allow to demonstrate a significant role of the chemerin/ChemR23 system (possibly as a result of the lack of production of active chemerin in these models), infection by either the Pneumonia Virus of Mice (PVM), the mouse counterpart of human RSV, or by a murinized H1N1 influenza strain resulted in a significantly higher mortality rate in ChemR23-/- mice as compared to their WT counterparts. Using the PVM-induced pneumonia model, we observed that the excessive mortality of knock-out mice is caused by an inadequate and excessive innate immune response characterized by a massive recruitment of neutrophils to the lungs, associated with a delayed viral clearance and lower type I IFN synthesis. This latter observation suggested an impairment of pDC recruitment, according to the important contribution of pDCs to the production of type I IFNs in viral diseases, and the role of chemerin in the recruitment of these cells. We indeed confirmed a lower recruitment of pDCs in the lung of infected ChemR23-/- mice, as compared to WT mice. However, experiments of adoptive transfert and depletion of pDCs failed to proof a link between impaired pDC recruitment and the excessive morbidity and mortality observed in ChemR23-invalidated mice. <p>In parallel, we studied the role of the chemerin/ChemR23 system in the control of innate immune responses, by using a model of acute lung injury caused by the intra-tracheal instillation of bacterial lipopolysaccharide (LPS). In this model, administration of recombinant chemerin together with LPS in WT mice resulted in a significant (about 50%) reduction of neutrophil recruitment to both lung parenchyma and airways. Assessment of pro-inflammatory cytokines and chemokines in broncho-alveolar lavage fluids confirmed this anti-inflammatory effect of chemerin, which was ChemR23-dependent, as the inflammatory response of ChemR23-/- mice was unaffected by chemerin. In our hands, chemerin does not modulate macrophage functions, in contrast to data recently published by other groups, attributing anti-inflammatory effects of chemerin or chemerin-derived peptide to the modulation of macrophage activation and phagocytosis. Other hypotheses that could take our observations into account are presently investigated, including an immunomodulatory role of chemerin on lung epithelial or endothelial cells, and/or the ChemR23-dependent recruitment of subtypes of macrophages or other myeloid cells endowed with immunosuppressive properties. <p>In conclusion, our studies characterized the mouse chemerin/ChemR23 system and highlighted the role of this system in the physiopathology of some inflammatory lung diseases. Our results suggest that the chemerin/ChemR23 system might be considered as a potential therapeutic target for the development of future anti-infectious and anti-inflammatory therapies, particularly for viral pneumonia, which represent a major public health problem, as well as for acute respiratory distress syndrome (ARDS) following severe acute lung injuries.<p> <p><p>Les agents chimioattractants jouent un rôle fondamental dans l’initiation des réponses immunes en régulant le trafic et la fonction des populations leucocytaires. Leurs récepteurs constituent dès lors des cibles d’intérêt pour le développement de traitements contre les maladies inflammatoires et le cancer. Le laboratoire d’accueil a identifié le récepteur ChemR23, exprimé à la surface des cellules dendritiques myéloïdes (mDCs) et plasmacytoïdes (pDCs) immatures, des macrophages, des cellules NK, des adipocytes, et des cellules endothéliales. Le ligand endogène du récepteur ChemR23, la chémérine, est présent en abondance dans divers échantillons pathologiques d’origine inflammatoire. La chémérine est produite sous la forme d'un précurseur inactif, la prochémérine, qui nécessite pour devenir active le clivage protéolytique de six ou sept acides aminés à son extrémité carboxy-terminale. La chémérine induit le chimiotactisme des macrophages et des DCs immatures, et en particulier des pDCs immatures en accord avec l’expression plus importante de ChemR23 par les pDCs. Les pDCs jouent un rôle immunorégulateur important en pathologie pulmonaire, en particulier dans la physiopathologie des pneumonies virales, par leur capacité à produire d’importantes quantités d’interféron (IFN) de type I.<p>Compte tenu de ces éléments et du rôle des polynucléaires neutrophiles dans de nombreuses pathologies pulmonaires, ainsi que dans la génération de chémérine active à partir de son précurseur, nous avons débuté en octobre 2007, l’étude du rôle de la chémérine et de son récepteur ChemR23 dans le contrôle des pathologies pulmonaires inflammatoires. Nous avons tout d’abord caractérisé le système chémérine/ChemR23 chez la souris et avons montré que ce système présentait des caractéristiques similaires à celles décrites chez l’homme, en termes de distribution, de pharmacologie et de propriétés fonctionnelles. <p>Ensuite, nous avons comparé des souris sauvages et invalidées pour le récepteur ChemR23 (ChemR23-/-) dans divers modèles de pathologies pulmonaires. Les modèles d’asthme et de fibrose pulmonaire induite par instillation de bléomycine ou de silice n’ont pas permis de mettre en évidence un rôle important du couple chémérine/ChemR23, peut-être en raison de l’absence de génération de forme active de chémérine dans ces modèles. En revanche, l’administration de deux agents viraux différents, le PVM (Pneumonia Virus of Mice), l’équivalent murin du RSV humain, et un virus de l’influenza H1N1 murinisé, a résulté en un taux de mortalité 40% plus élevé pour les souris ChemR23-/- par rapport à leurs homologues sauvages. En utilisant le modèle de pneumonie induite par le PVM, nous avons montré que cette différence de mortalité est causée par une réponse immune inappropriée et excessive, associée à une réduction de l’élimination du virus, ainsi qu’à un déficit de synthèse d’IFN de type I. Les pDCs, dans un contexte d’infection virale, sont capables de synthétiser d’importantes quantités d’IFN de type I, et nous avons mis en évidence un déficit relatif de recrutement en pDCs chez les souris ChemR23-/- infectées. Néanmoins, les expériences de transfert adoptif et de déplétion de pDCs n’ont pas permis de lier ce défaut de recrutement à l’excès de morbidité et de mortalité observé chez les souris ChemR23-/- infectées. <p>En parallèle, le rôle de ce couple ligand-récepteur dans le contrôle des réponses immunitaires innées a été étudié dans un modèle de pneumopathie aiguë induite par instillation intra-trachéale de lipopolysaccharide (LPS). Dans ce modèle, l’administration simultanée de chémérine recombinante avec le LPS entraîne chez les souris sauvages une diminution significative (environ 50%) du nombre de polynucléaires neutrophiles recrutés dans les voies aériennes et dans le parenchyme pulmonaire, ainsi qu’une importante diminution de synthèse de cytokines pro-inflammatoires. Cet effet anti-inflammatoire de la chémérine est dépendant de ChemR23, et ne semble pas être secondaire à un effet de la chémérine sur l’activation des macrophages, contrairement à certaines données publiées récemment par d’autres groupes. D’autres hypothèses permettraient cependant de prendre en compte ces observations, notamment un effet de la chémérine sur les cellules épithéliales et/ou endothéliales pulmonaires, ainsi que sur le recrutement de sous-populations de macrophages ou d’autres cellules myéloïdes possédant des propriétés immunosuppressives. Des expériences complémentaires ont été initiées afin de tester ces hypothèses. <p>En conclusion, après avoir caractérisé le système chémérine/ChemR23 chez la souris, nos études ont permis de mettre en évidence le rôle de ce couple ligand/récepteur dans la physiopathologie de certaines pneumopathies inflammatoires, ouvrant ainsi de nouvelles perspectives thérapeutiques, en particulier pour le traitement des pneumopathies virales, qui constituent un problème de santé publique majeur, ainsi que des syndromes de détresse respiratoire aiguë (ARDS). / Doctorat en Sciences médicales / info:eu-repo/semantics/nonPublished

Le métapneumovirus humain (hMPV) est un virus responsable d'infections aiguës des voies respiratoires telles que des bronchiolites, des bronchites ou des pneumonies, principalement chez les populations à risques que sont les jeunes enfants de moins de 5 ans, ainsi que les personnes âgées ou immunodéprimées. Découvert en 2001, ce virus et sa pathogénèse ne restent encore aujourd'hui que partiellement caractérisés. De ce fait et malgré les besoins, il n'y a aucun vaccin ou traitement thérapeutique spécifique et efficace contre le HMPV disponible sur le marché. Dans ce contexte, mon projet de thèse s'est articulé autour de deux axes principaux : (i) L'étude de la protéine de fusion F du virus hMPV, protéine majeure antigénique de surface et responsable de l'entrée du virus dans la cellule cible. Elle a pour particularité d'induire de manière autonome la fusion membranaire in vitro et d'être associée à des effets cytopathiques variable selon les souches virales. De par son rôle clé pour le virus hMPV, la protéine F a déjà fait l'objet de plusieurs études structurales et fonctionnelles mais les déterminants de cette activité fusogénique ne sont pas encore entièrement caractérisés. Nous nous sommes donc intéressés à l'identification de déterminants du phénotype viral hyperfusogénique, localisés dans les domaines heptad repeats de la protéine F du hMPV. (ii) L'atténuation de deux souches virales cliniques (CAN98-75 et C-85473) par délétion de gènes accessoires dans le but de développer des candidats vaccinaux adaptés aux enfants en bas âge. Différents virus ont été générés par génétique inverse et les délétions des gènes accessoires SH et G dans les deux fonds génétiques viraux ont été étudiées pour leur impact sur l'infectivité, la réplication et la pathogénèse virale in vitro et in vivo ainsi que leur contribution pour le développement de virus atténués candidats vaccinaux / Human metapneumovirus (hMPV) is a major pathogen responsible of acute respiratory tract infections, such as bronchiolitis or pneumonia, affecting especially infants, under five years old, elderly individuals and immunocompromised adults. Identified since 2001, this virus and its pathogenesis still remain largely unknown and no licensed vaccines or specific antivirals against hMPV are currently available. In this context, my research project was built over two main subjects: (i) The study of the fusion F glycoprotein which is the major antigenic protein of hMPV and is responsible of viral entry into host cell. By its crucial role for the virus, the F protein has already been characterized in several structural and/or functional studies. Thus, it has been described that the hMPV F protein induces membrane fusion autonomously, resulting in variable cytopathic effects in vitro, in a strain-dependent manner. However, as the determinants of the hMPV fusogenic activity are not well characterized yet, we focused on identification of some of these, located in heptad repeats domains of the protein. (ii) The evaluation of hMPV SH and G gene deletion for viral attenuation. Liveattenuated hMPV vaccine candidates for infants’ immunization has been constructed thank to this deletion approach at the beginning of hMPV vaccine development efforts. Despite encouraging results, these candidates have not been further characterized and the importance of the viral background has not been evaluated

Influenzavirus (IV)-Infektionen der unteren Atemwege induzieren virale Pneumonien, die häufig in akutem Lungenversagen resultieren. Merkmale einer IV-induzierten Pneumonie sind Schädigungen des Alveolarepithels und eine Ansammlung von Ödemflüssigkeit im Alveolarraum, wodurch der Gasaustausch beeinträchtigt wird. In Abhängigkeit eines Natriumgradienten, aufgebaut durch die basolaterale Na,K-ATPase (NKA) und den apikalen epithelialen Natriumkanal (ENaC), wird unter normalen Bedingungen die Ödemflüssigkeit aus dem Alveolarraum entfernt. In Folge einer IV-Infektion werden verschiedene Membranionenkanäle dysreguliert und eine verringerte alveoläre Flüssigkeitsresorption (AFC) beobachtet. Eine IV-Infektion führt u.a. zu einer reduzierten NKA-Expression in nicht-infizierten Nachbarzellen, sowie zu einer Dislokation der NKA zur apikalen Zellmembran in infizierten Zellen. Co-Immunopräzipitationsstudien identifizierten das virale M2-Protein als NKA-Bindepartner. Mittels Mutationsanalyse konnten drei Aminosäuren im zytoplasmatischen Teil von M2 als kritisch für die NKA-Bindung identifiziert werden. Rekombinante IV mit gestörter NKA Bindung zeigten im Vergleich zu IV WT in polarisierten Calu 3 Zellen in vitro sowie in Mäusen in vivo eine verbesserte AFC. Eine mutationsbedingte Glykosylierung des M2-Proteins führte jedoch unerwartet zu einer verstärkten Immunantwort in vivo, die trotz verbesserter AFC zu einem schwereren Krankheitsverlauf führte. Grund dafür könnte eine Aktivierung der Unfolded Protein Response aufgrund der Glykosylierung sein. Die Erkenntnis, dass M2 ein wichtiger Modulator in der Regulation der alveolären Flüssigkeitshomöostase ist, könnte dennoch helfen, neue therapeutische Ansätze für IV-induzierte Pneumonien zu definieren. Darüber hinaus unterstreicht es die Relevanz einer in der vorliegenden Arbeit durchgeführten Surfactome-Analyse zur Identifizierung neuer potentieller Angriffspunkte an der Zelloberfläche IV-infizierter Zellen, die in der antiviralen Therapie von Bedeutung sein könnten. / Influenza Virus (IV) infections of the lower respiratory tract can induce viral pneumonia resulting in acute lung injury (ALI/ARDS) with fatal outcome. Characteristics of an IV-induced pneumonia are alveolar epithelial cell (AEC) damage and accumulation of protein-rich edema fluid in the alveolar compartment impairing gas exchange. Depending on a sodium gradient established by the basolateral Na,K-ATPase (NKA) and the apical epithelial sodium channel (ENaC) edema fluid is removed from the alveolar space under normal conditions. However, after IV-infection various ion channels are dysregulated and reduced alveolar fluid clearance (AFC) is observed. An IV-infection leads to a reduced NKA expression in the non-infected neighbouring cells and to a mistargeting of the NKA to the apical cell membrane in IV-infected cells. Co immunoprecipitation (co-IP) studies identified the viral M2 protein as NKA binding partner and mutational analysis presented three amino acids in the cytoplasmic tail of M2 directly abutting the transmembrane domain as critical for NKA binding. A recombinant IV mutant with disrupted NKA binding showed in comparison to IV WT an increased fluid transport in polarized Calu 3 cells in vitro as well as in mice in vivo. However, mutation-induced glycosylation of the M2 protein unexpectedly led to an enhanced immune response in vivo, resulting in a more severe disease course despite improved AFC. The reason for this could be an activation of the unfolded protein response by the glycosylation of M2. Nevertheless, the finding that M2 appears to be an important modulator in the regulation of alveolar fluid homeostasis might provide new potential approaches for therapeutics of an IV induced pneumonia. Moreover, it highlights the relevance of a surfactome analysis performed in the present work to identify novel potential targets on the cell surface of IV-infected cells which could play an important role in antiviral therapy.